Prof Glyn Taylor - BSc PhD MIoD
Glyn Taylor is Professor of Drug Delivery and Director of Collaborative Provision for the MPharm and BPharm programmes delivered at Taylor’s University School of Pharmacy, in Malaysia. He is also Chairman of the Cardiff University spin-out ventures Cardiff Scintigraphics and i2c Pharmaceutical Services.
He graduated with a BSc in Pharmacy from Aston University in 1976 and a PhD in Pharmacokinetics from Manchester University in 1981. He joined the faculty of the Welsh School of Pharmacy in Cardiff during 1980 and was subsequently appointed as a Research Fellow in Clinical Pharmacology at Stanford University (1982-1983) and as a Visiting Assistant Professor at the University of California, San Francisco, School of Pharmacy (1989-1990).
In 1992, he co-founded Cardiff Scintigraphics, a Cardiff University spin-out company focussed on the clinical and in vitro evaluation of pharmaceuticals and drug delivery systems using techniques including gamma scintigraphy. In addition to a joint venture with Europe’s longest established Clinical Research Organisation Simbec, the spin-out company has also focused on novel (non-CFC) formulation strategies for inhalation drug delivery. He has delivered many lectures to academic, industrial and commercial organisations in the UK and in the US and has authored or co-authored more than 150 research articles, in the areas of pharmacokinetics, biopharmaceutics and gamma scintigraphy. To date, 20 graduate students have been awarded PhD degrees under his supervision.
His overall research aim is to elucidate factors which influence variability in pharmacokinetics. This encompasses both pre-clinical investigations of formulation excipients on drug delivery and absorption and clinical investigations using gamma scintigraphy to investigate patient and device variables on the optimisation of drug deposition and delivery to appropriate absorption sites, particularly the lung.
Scientific & Professional Service
Glyn is a reviewer for BBSRC, Wellcome Foundation and is a member of the Bioequivalence Ad Hoc Group of the MHRA.